Vaccines are the most effective strategy to mitigate the global impact of COVID-19. However, vaccine hesitancy is common, particularly among minorities. Guillain-Barré syndrome (GBS) is the most common autoimmune illness of the peripheral nervous system, occurring at an incidence of 1.1/100,000 worldwide. A causal link between mRNA vaccines and GBS has not been previously evaluated. We analyzed a cohort of 3,890,250 Hispanic/Latinx recipients of the BNT162b2 mRNA vaccine (613,780 of whom had already received both doses) for incident GBS occurring within 30 days from vaccine administration. Seven cases of GBS were detected among first-dose recipients, for an observed incidence of 0.18/100,000 administered doses during the prespecified timeframe of 30 days. No cases were reported after second-dose administration. Our data suggest that, among recipients of the BNT162b2 mRNA vaccine, GBS may occur at the expected community-based rate; however, this should be taken with caution as the current incidence of GBS among the unvaccinated population against COVID-19 is still undetermined. We hope that this preliminary data will increase the public perception of safety toward mRNA-based vaccines and reduce vaccine hesitancy.

疫苗是减轻 COVID-19 全球影响的最有效策略。然而，对疫苗的犹豫很常见，尤其是在少数族裔中。格林-巴利综合征 (GBS) 是周围神经系统最常见的自身免疫性疾病，全球发病率为 1.1/100,000。此前尚未评估过 mRNA 疫苗与 GBS 之间的因果关系。我们分析了 3,890,250 名 BNT162b2 mRNA 疫苗接种者（其中 613,780 名已经接种了两剂疫苗）的西班牙裔/拉丁裔接种者在接种疫苗后 30 天内发生的 GBS 事件。在第一剂接受者中发现了 7 例 GBS 病例，在预定的 30 天时间内观察到的发病率为 0.18/100,000 剂。第二剂给药后没有报告病例。我们的数据表明，在 BNT162b2 mRNA 疫苗的接受者中，GBS 可能会以基于社区的预期发生率发生；然而，这一点应谨慎对待，因为目前未接种 COVID-19 疫苗的人群中 GBS 的发病率仍不确定。我们希望这些初步数据能够提高公众对基于 mRNA 的疫苗的安全性的认知，并减少疫苗的犹豫。